These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

167 related articles for article (PubMed ID: 23604462)

  • 1. PPARg2 Ala¹² variant protects against Graves' orbitopathy and modulates the course of the disease.
    Pawlak-Adamska E; Daroszewski J; Bolanowski M; Oficjalska J; Janusz P; Szalinski M; Frydecka I
    Immunogenetics; 2013 Jul; 65(7):493-500. PubMed ID: 23604462
    [TBL] [Abstract][Full Text] [Related]  

  • 2. The Pro 12 Ala PPAR gamma gene polymorphism: possible modifier of the activity and severity of thyroid-associated orbitopathy (TAO).
    Alevizaki M; Mantzou E; Cimponeriu A; Saltiki K; Philippou G; Wiersinga W
    Clin Endocrinol (Oxf); 2009 Mar; 70(3):464-8. PubMed ID: 18624999
    [TBL] [Abstract][Full Text] [Related]  

  • 3. CD28/CTLA-4/ICOS haplotypes confers susceptibility to Graves' disease and modulates clinical phenotype of disease.
    Pawlak-Adamska E; Frydecka I; Bolanowski M; Tomkiewicz A; Jonkisz A; Karabon L; Partyka A; Nowak O; Szalinski M; Daroszewski J
    Endocrine; 2017 Jan; 55(1):186-199. PubMed ID: 27638540
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Association between polymorphisms in the TSHR gene and Graves' orbitopathy.
    Jurecka-Lubieniecka B; Ploski R; Kula D; Szymanski K; Bednarczuk T; Ambroziak U; Hasse-Lazar K; Hyla-Klekot L; Tukiendorf A; Kolosza Z; Jarzab B
    PLoS One; 2014; 9(7):e102653. PubMed ID: 25061884
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Clinical Implications of Immunoglobulin G4 to Graves' Ophthalmopathy.
    Yu SH; Kang JG; Kim CS; Ihm SH; Choi MG; Yoo HJ; Lee SJ
    Thyroid; 2017 Sep; 27(9):1185-1193. PubMed ID: 28805160
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Oxidative Stress and Upregulation of Antioxidant Proteins, Including Adiponectin, in Extraocular Muscular Cells, Orbital Adipocytes, and Thyrocytes in Graves' Disease Associated with Orbitopathy.
    Marique L; Senou M; Craps J; Delaigle A; Van Regemorter E; Wérion A; Van Regemorter V; Mourad M; Nyssen-Behets C; Lengelé B; Baldeschi L; Boschi A; Brichard S; Daumerie C; Many MC
    Thyroid; 2015 Sep; 25(9):1033-42. PubMed ID: 26176182
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Role of Proprotein Convertase Subtilisin/Kexin Type 9 in the Pathogenesis of Graves' Orbitopathy in Orbital Fibroblasts.
    Lee GE; Kim J; Lee JS; Ko J; Lee EJ; Yoon JS
    Front Endocrinol (Lausanne); 2020; 11():607144. PubMed ID: 33488522
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Soluble CTLA-4 receptor an immunological marker of Graves' disease and severity of ophthalmopathy is associated with CTLA-4 Jo31 and CT60 gene polymorphisms.
    Daroszewski J; Pawlak E; Karabon L; Frydecka I; Jonkisz A; Slowik M; Bolanowski M
    Eur J Endocrinol; 2009 Nov; 161(5):787-93. PubMed ID: 19734241
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Polymorphisms of endothelin 1 (G5665T and T-1370G) and endothelin receptor type A (C+70G and G-231A) in Graves' disease.
    Aydın AF; Develi-İş S; Doğru-Abbasoğlu S; Vural P; Ozderya A; Karadağ B; Uysal M
    Int Immunopharmacol; 2014 Jan; 18(1):198-202. PubMed ID: 24291390
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Type 2 diabetic patients with Graves' disease have more frequent and severe Graves' orbitopathy.
    Le Moli R; Muscia V; Tumminia A; Frittitta L; Buscema M; Palermo F; Sciacca L; Squatrito S; Vigneri R
    Nutr Metab Cardiovasc Dis; 2015 May; 25(5):452-7. PubMed ID: 25746910
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Prevalence of Graves' ophthalmopathy in patients with Graves' disease presenting to a referral centre in north India.
    Reddy SV; Jain A; Yadav SB; Sharma K; Bhatia E
    Indian J Med Res; 2014 Jan; 139(1):99-104. PubMed ID: 24604044
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Influence of the TSH receptor gene on susceptibility to Graves' disease and Graves' ophthalmopathy.
    Yin X; Latif R; Bahn R; Tomer Y; Davies TF
    Thyroid; 2008 Nov; 18(11):1201-6. PubMed ID: 18925838
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Human placenta-derived mesenchymal stem cells ameliorate orbital adipogenesis in female mice models of Graves' ophthalmopathy.
    Park M; Banga JP; Kim GJ; Kim M; Lew H
    Stem Cell Res Ther; 2019 Aug; 10(1):246. PubMed ID: 31399042
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Influence of biological sex, age and smoking on Graves' orbitopathy - a ten-year tertiary referral center analysis.
    Oeverhaus M; Winkler L; Stähr K; Daser A; Bechrakis N; Stöhr M; Chen Y; Eckstein A
    Front Endocrinol (Lausanne); 2023; 14():1160172. PubMed ID: 37082130
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Search of reference biomarkers reflecting orbital tissue remodeling in the course of Graves' orbitopathy.
    Pawlowski P; Poplawska I; Mysliwiec J; Dik WA; Eckstein A; Berchner-Pfannschmidt U; Milewski R; Lawicki S; Dzieciol-Anikiej Z; Rejdak R; Reszec J
    Folia Histochem Cytobiol; 2020; 58(1):37-45. PubMed ID: 32176314
    [TBL] [Abstract][Full Text] [Related]  

  • 16. A novel thyroid stimulating immunoglobulin bioassay is a functional indicator of activity and severity of Graves' orbitopathy.
    Lytton SD; Ponto KA; Kanitz M; Matheis N; Kohn LD; Kahaly GJ
    J Clin Endocrinol Metab; 2010 May; 95(5):2123-31. PubMed ID: 20237164
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Poly (ADP-ribose) polymerase-1 (PARP-1) in Chinese patients with Graves' disease and Graves' ophthalmopathy.
    Wu T; Tang DR; Zhao L; Sun FY
    Can J Physiol Pharmacol; 2018 Jun; 96(6):556-561. PubMed ID: 28177666
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Association of variant on the promoter of cluster of differentiation 74 in graves disease and graves ophthalmopathy.
    Liu YH; Shen CY; Tsai FJ
    Biosci Rep; 2020 Aug; 40(8):. PubMed ID: 32744317
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Association between methylenetetrahydrofolate reductase (MTHFR) polymorphisms and susceptibility to Graves' ophthalmopathy.
    Lee JY; Kim NK; Cho YW; Lew H
    Mol Med Rep; 2016 Sep; 14(3):2276-82. PubMed ID: 27430300
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Serum antibodies against the insulin-like growth factor-1 receptor (IGF-1R) in Graves' disease and Graves' orbitopathy.
    Marinò M; Rotondo Dottore G; Ionni I; Lanzolla G; Sabini E; Ricci D; Sframeli A; Mazzi B; Menconi F; Latrofa F; Vitti P; Marcocci C; Chiovato L
    J Endocrinol Invest; 2019 Apr; 42(4):471-480. PubMed ID: 30132285
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.